Atomic AI
Atomic AI develops ATOM-1, an RNA foundation model that predicts RNA structure and function to discover RNA-targeted therapeutics.
Founded
2021Atomic AI develops ATOM-1, an RNA foundation model that predicts RNA structure and function to discover RNA-targeted therapeutics.
Atomic AI's ATOM-1 is differentiated by its foundation model trained specifically on chemical mapping data for RNA, a modality historically considered difficult to drug. The platform combines deep-learning structure prediction with proprietary wet-lab assays, creating a closed loop of computational design and experimental validation.
The company also benefits from a founding team with deep expertise at the intersection of machine learning and RNA biology, and early backing from Playground Global, positioning it competitively against broader AI drug-discovery platforms.
Source: atomic.ai
Atomic AI describes its work as RNA-focused drug discovery combining machine learning with experimental data generation. Its current partnering page invites other companies to apply ATOM-1 to programs aligned with their therapeutic priorities.
The reviewed public materials establish a direct business-development contact route for partnerships, while the December 2023 model release describes internal pipeline ambitions. They do not disclose commercial pricing, a recurring revenue contract, or a global market footprint; those details remain unclassified pending a company disclosure.
Source: atomic.ai
ATOM-1 is Atomic AI's flagship product: a proprietary RNA foundation model trained on chemical mapping data. It predicts RNA structure and function with atomic precision and is integrated with in-house wet-lab assays to discover RNA-targeted small molecules and RNA-based therapeutics.
The platform is designed as a virtuous cycle of machine learning and structural biology, enabling the company to unlock previously undruggable RNA targets and advance a pipeline of RNA-centric medicines.
Source: atomic.ai